<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545464</url>
  </required_header>
  <id_info>
    <org_study_id>P160913</org_study_id>
    <nct_id>NCT03545464</nct_id>
  </id_info>
  <brief_title>COrticosteroids in acUte uRticAria in emerGency dEpartment</brief_title>
  <acronym>COURAGE</acronym>
  <official_title>COrticosteroids in acUte uRticAria in emerGency dEpartment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the non-inferiority of the efficacy of a single antihistamine in comparaison
      with an association of antihistamine and corticosteroid in the treatment of acute urticaria
      in emergency departments
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute urticaria (hives) is a common skin disease. The prevalence of acute urticaria in life
      is about 15 to 20% in the general population. It is responsible for a frequent use of
      emergency departments (ED). The usual treatment is based on early administration of an
      association of antihistamines and corticosteroid. The therapeutic efficacy of corticosteroids
      has never been established by high evidence studies. However, corticosteroids are frequently
      used. When stopped, corticosteroids could promote the occurence of urticaria recurrences, and
      a transition to chronic urticaria. In addition, corticosteroids may be rarely responsible for
      gastrointestinal bleeding, hypertension and diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-Days Urticaria Activity Score (UAS 7) at day 7</measure>
    <time_frame>For 7 day</time_frame>
    <description>Urticaria Activity Score (UAS) is a daily combined score of severity of itch and number of hives. Each component of the UAS is scored on a scale of 0 to 3; the 2 scores are added together for a daily total of 0 to 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of hives at day 7 and/or recurrence of itch at day 7</measure>
    <time_frame>For 7 day</time_frame>
    <description>The UAS 7 is the sum of the daily UAS scores over 7 days. This questionnaire will be completed by the patient and the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of spontaneous wheals and/or itch for &gt; 6 weeks</measure>
    <time_frame>beyond 6 Weeks</time_frame>
    <description>wheals and/or itch for &gt; 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with angioedema at day 7, 14 and 3 months</measure>
    <time_frame>up to 3 month</time_frame>
    <description>angioedema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The reduction of morbidity is assessed by new emergency visits for acute urticaria recurrences at day 7, 14 and 3 months</measure>
    <time_frame>up to 3 month</time_frame>
    <description>emergency visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(DLQI) up to 6 months</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The DLQI is a dermatology-specific quality of life questionnaire designed for use in patients over 16 years of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cu-Q2QoL up to 6 months</measure>
    <time_frame>at day 7, at day 14, at 6 week, at 3 months and 6 months</time_frame>
    <description>The CU-Q2oL (French version) is a questionnaire that measures the relative burden of chronic urticaria on subjective well-being</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Urticaria</condition>
  <condition>Angiœdema</condition>
  <arm_group>
    <arm_group_label>Antihistamines + placebo of cortancyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- In emergency department : Levocetirizine 5 mg orally. Renewable once if persistence of hives at 30 minutes.
Placebo of Cortancyl : 1mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally
- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).
Placebo of Cortancyl 20 mg x 2 tablets = 40mg once per day for 3 days orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Association of antihistamines and cortancyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>- In emergency department : Levocetirizine 5 mg orally Renewable once if persistence of hives at 30 minutes.
Cortancyl: 1 mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally.
- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).
Cortancyl : 20 mg x 2 tablets = 40 mg per day for 3 days orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo of cortancyl Oral Tablet 20mg</description>
    <arm_group_label>Antihistamines + placebo of cortancyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cortancyl Oral Tablet</intervention_name>
    <description>Cortancyl oral Tablet 20 mg</description>
    <arm_group_label>Association of antihistamines and cortancyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine Oral Tablet</intervention_name>
    <description>Levocetirizine Oral Tablet 5 mg</description>
    <arm_group_label>Antihistamines + placebo of cortancyl</arm_group_label>
    <arm_group_label>Association of antihistamines and cortancyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Isolated acute urticaria (acute hives): spontaneous urticaria, inducible urticaria

          -  Acute urticaria with angioedema without laryngeal edema

          -  Obtain patient's consent

          -  Social security affiliation

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  Acute hives with anaphylaxis

          -  Bradykinin angioedema

          -  Angioedema without urticaria (hives)

          -  Laryngeal edema with urticaria (hives)

          -  Corticosteroid administration in the previous 5 days visiting the emergency department

          -  Antihistamines greater than 1 tablet per day in the previous 5 days visiting the ED

          -  Other treatment for urticaria : omalizumab, montelukast, ciclosporine A

          -  Chronic urticaria before acute urticaria diagnosis

          -  Atopic dermatitis

          -  Eczema

          -  Bullous pemphigoid

          -  Acute exanthematous pustulosis

          -  Diabetes mellitus

          -  Gastrointestinal ulcer

          -  Refusal to participate

          -  Known allergy to the study drugs or formulation ingredients

          -  Known Renal failure defined by creatinine clearance &lt; 10 mL/min or cardiac failure
             defined by ejection fraction &lt; 40%.

          -  Corticoid use in 5 days prior to randomisation

          -  Contra-indication to corticotherapy:

          -  Any live vaccine

          -  Psychotic states still uncontrolled by treatment limiting the participant's compliance
             with the research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas JAVAUD, M.D,Ph.D</last_name>
    <phone>+33 1 47 60 64 42</phone>
    <email>nicolas.javaud@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fréderic ADNET, M.D,Ph.D</last_name>
    <phone>+33 1 48 96 44 08</phone>
    <email>frederic.adnet@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Louis MOURIER</name>
      <address>
        <city>Colombes</city>
        <state>Ile De France</state>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas JAVAUD, M.D, Ph.D</last_name>
      <phone>+33 1 47 60 64 42</phone>
      <email>nicolas.javaud@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute urticaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

